New Research Study Provides Further Evidence of Strong Correlation of TriPath Imaging's ProEx C Biomarkers with Biopsy Evidence
07 Noviembre 2005 - 10:46AM
PR Newswire (US)
In-house and External Retrospective Research Studies Incorporating
ProEx C Biomarkers Presented at 53rd Annual Scientific Meeting of
the American Society of Cytopathology BURLINGTON, N.C., Nov. 7
/PRNewswire-FirstCall/ -- TriPath Imaging, Inc. (NASDAQ:TPTH) today
announced that the results of a new in-house retrospective research
study demonstrated that testing of cervical cytology specimens with
Research Use Only (RUO) reagents incorporating the Company's
proprietary ProEx C biomarkers yielded a 93% (p
Tripath Imaging (NASDAQ:TPTH)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Tripath Imaging (NASDAQ:TPTH)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Tripath Imaging (NASDAQ): 0 recent articles
Más de Tripath Imaging Inc. (MM) Artículos de Noticias